NCT03985384

Semaglutide Treatment On Coronary Progression

Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.

Detailed description

To determine the effects of semaglutide therapy on the morphology and composition of non-calcified coronary atherosclerotic plaque (NCP), including the progression of plaque volume.

Conditions

• Type 2 Diabetes
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Semaglutide 2 MG/1.5 ML Subcutaneous Solution	Semaglutide 2 MG/1.5 ML Subcutaneous Solution
DRUG	Placebo	Placebo 1.5 ml, pen-injector for SC injection.

Timeline

• Start date: 2019-04-30
• Primary completion: 2022-12-27
• Completion: 2022-12-27
• First posted: 2019-06-13
• Last updated: 2023-10-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study